These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9035043)

  • 1. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategic proposals to avoid toxic drug interactions during new drug development: molecular toxicology proposals.
    Kamataki T; Yokoi T; Yamayoshi Y; Nakamura K; Kushida H; Fujita K; Mitsuhashi H; Ueno T
    J Toxicol Sci; 1996 Dec; 21(5):305-8. PubMed ID: 9035042
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug--proposals for designing non-clinical and clinical studies--is the non-clinical study useful?
    Ozawa N
    J Toxicol Sci; 1996 Dec; 21(5):323-9. PubMed ID: 9035045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug interactions. Mechanisms and clinical relevance].
    Klotz U; Beil W; Gleiter C; Drewelow B; Garbe E; Gillessen A; Mutschler E
    Internist (Berl); 2003 Nov; 44(11):1444-9. PubMed ID: 14689079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs and the liver.
    Reidenberg MM; Breckenridge A
    Clin Pharmacol Ther; 1998 Oct; 64(4):353-4. PubMed ID: 9797790
    [No Abstract]   [Full Text] [Related]  

  • 7. A proposal for avoiding toxic interactions of a drug under development to estimate inhibitory ability on the drug metabolizing enzymes in human liver.
    Noguchi H
    J Toxicol Sci; 1996 Dec; 21(5):317-21. PubMed ID: 9035044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FOOD - DRUG INTERACTIONS: TYPES AND MECHANISMS.].
    Lemina EY; Churyukanov VV
    Eksp Klin Farmakol; 2016; 79(11):41-44. PubMed ID: 29791108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial. Role of Drug Transport and Pharmacokinetics in Drug Efficacy and Safety Part 1.
    Liu C; He X
    Curr Drug Metab; 2015; 16(9):730-1. PubMed ID: 26630904
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinically relevant adverse drug interactions].
    Martin-Facklam M; Haefeli WE
    Ther Umsch; 2000 Sep; 57(9):579-83. PubMed ID: 11036439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
    Bodor N; Buchwald P
    Mol Biotechnol; 2004 Feb; 26(2):123-32. PubMed ID: 14764938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics in the drug regulatory process.
    Salmonson T; Rane A
    Clin Pharmacokinet; 1990 Mar; 18(3):177-83. PubMed ID: 2323153
    [No Abstract]   [Full Text] [Related]  

  • 14. Current drug metabolism.
    Kerns EH
    Curr Drug Metab; 2008 Nov; 9(9):845-6. PubMed ID: 18991579
    [No Abstract]   [Full Text] [Related]  

  • 15. Manufacturing uncertainty: adverse effects of drug development for women.
    Peppin P
    Int J Law Psychiatry; 2003; 26(5):515-32. PubMed ID: 14522223
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards rational drug therapy in old age. The F.E. Williams Lecture 1985.
    Caird FI
    J R Coll Physicians Lond; 1985 Oct; 19(4):235-9. PubMed ID: 4067897
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of pharmacokinetics in drug safety evaluation.
    Singhvi SM; Keim GR; Migdalof BH
    Regul Toxicol Pharmacol; 1985 Mar; 5(1):3-17. PubMed ID: 3991931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-herb interactions: eliminating toxicity with hard drug design.
    Yang XX; Hu ZP; Duan W; Zhu YZ; Zhou SF
    Curr Pharm Des; 2006; 12(35):4649-64. PubMed ID: 17168768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review.
    Sohn HS; Kim H; Song IS; Lim E; Kwon M; Ha JH; Kwon JW
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):621-34. PubMed ID: 26104035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.